CURE

FDA Accepts Gedatolisib Application for Some With Breast Cancer

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for gedatolisib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA ...
Nasdaq

Fortress Biotech's Cyprium Therapeutics Receives Priority Review for CUTX-101 New Drug Application with Target Action Date of June 30, 2025

Priority Review granted for CUTX-101 could expedite its path to market, potentially becoming the first FDA-approved treatment for Menkes disease. Cyprium is eligible to receive up to $129 million in ...
Security Boulevard

How Attackers Target Financial Applications and VAPT Stops Them?

Financial applications, ranging from mobile banking apps to payment gateways, are among the most targeted systems worldwide. In 2025 alone, the Indusface State of Application Security Report revealed ...
Seeking Alpha

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

FDA assigned PDUFA target action date of July 7, 2026. If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN. Atacicept received FDA Breakthrough Therapy ...